SS-31 (Elamipretide) Failed Its Biggest Trial. Then Got FDA Approval. Here's Why.

In 2023, a 218-patient randomized trial concluded that SS-31 did nothing for mitochondrial disease. Two years later, the FDA approved it. That apparent contradiction is the most important thing to understand before spending anything on this peptide: SS-31 does not treat "mitochondrial dysfunction" as a general category. It repairs one specific molecular failure with unusual precision, and produces near-zero results everywhere else.

The MMPOWER-3 trial, published in Neurology in 2023, enrolled patients with "primary mitochondrial myopathy" defined broadly across dozens of genetic subtypes. Participants received 40 mg per day of elamipretide (the pharmaceutical name for SS-31) for 24 weeks. The 6-minute walk test improvement versus placebo was minus 3.2 meters. The fatigue score difference was 0.07 points. No statistical significance on either primary endpoint.

That result did not end the program. It clarified it. The TAZPOWER trial, running in parallel, enrolled 12 patients with Barth syndrome only. Barth syndrome is caused by mutations in the tafazzin (TAZ) gene, which directly impairs cardiolipin remodeling on the inner mitochondrial membrane. SS-31 addresses that exact defect. At week 36, Barth syndrome patients gained 95.9 meters on the 6-minute walk test and improved knee extensor strength by more than 45 percent. The FDA granted accelerated approval in September 2025 under the brand name FORZINITY, making SS-31 the first approved mitochondrial-targeted therapeutic in history.

What does SS-31 actually do inside a mitochondrion?

SS-31 (D-Arg-Dmt-Lys-Phe-NH2) is a tetrapeptide that accumulates more than 1,000-fold inside mitochondria within minutes of subcutaneous injection. That selectivity is its main practical advantage over broad antioxidants like CoQ10 or MitoQ, which distribute throughout the cell without targeting the inner membrane specifically.

Inside the mitochondrial inner membrane, SS-31 binds cardiolipin. Cardiolipin has two critical jobs: anchoring electron transport chain complexes (I through IV) into stable supercomplexes that maximize ATP synthesis efficiency, and preventing cytochrome c from converting into a peroxidase enzyme that generates destructive reactive oxygen species. When cardiolipin oxidizes, as it does progressively with aging and acute ischemic stress, both functions fail simultaneously. Electron leak increases, ATP production drops, and cytochrome c starts attacking the very membrane structure it is supposed to sit inside.

The ATP output data from preclinical models is consistent and striking. Under conditions where cardiolipin oxidative damage is the primary insult, SS-31 restores ATP production by 20 to 40 percent. In cardiac ischemia-reperfusion models with documented cardiolipin remodeling, improvements in left ventricular function are reproducible across multiple independent research groups. The problem has never been mechanism plausibility. The problem has always been identifying which patients have cardiolipin failure as their rate-limiting bottleneck.

Why did SS-31 fail 218 patients and still get FDA approved?

The MMPOWER-3 population was heterogeneous by design. Any confirmed mitochondrial gene defect qualified a patient. That meant the trial enrolled people with Complex I assembly defects, mitochondrial DNA deletion syndromes, POLG mutations, SURF1 defects, and dozens of other genetic causes, almost none of which involve tafazzin-dependent cardiolipin remodeling as their primary failure mode. Asking SS-31 to fix heterogeneous mitochondrial disease is like asking a carburetor repair specialist to fix every car breakdown: occasionally relevant, usually not.

"The discordance between MMPOWER-3 and TAZPOWER illustrates a fundamental challenge in mitochondrial medicine: treating a heterogeneous syndrome with a mechanism-specific compound requires patient selection based on the target pathway, not the clinical syndrome."

Neurology, 2023 (MMPOWER-3 primary results)

The FDA's path to approval was not straightforward. A Cardiovascular and Renal Drugs Advisory Committee voted 10 to 6 in favor of approval in October 2024, reflecting genuine scientific disagreement about whether knee extensor strength in 12 patients constitutes adequate evidence. The agency approved under the accelerated pathway in September 2025, using muscle strength as an intermediate clinical endpoint, on the grounds that Barth syndrome is life-limiting, the unmet medical need is extreme, and the biology of tafazzin and cardiolipin gives the mechanism scientific plausibility. A confirmatory trial to establish clinical benefit is ongoing.

What does the evidence say for aging and performance in healthy adults?

Promising mechanism, no completed randomized controlled trials in healthy populations. That is the honest summary.

The PROGRESS-HF Phase 2 trial, published in Circulation Heart Failure, enrolled heart failure patients and found a 14 mL reduction in left ventricular end-systolic volume (p=0.005) after a single intravenous dose. That is a structurally meaningful cardiac endpoint, not just a biomarker. A chronic dosing follow-up trial did not replicate the benefit at the primary endpoint, which fits the pattern seen elsewhere: SS-31 produces clear acute signals where cardiolipin damage is the primary driver, and weaker chronic effects in populations where it is one of many contributing factors.

For longevity users, the inference chain runs like this. Cardiolipin content in muscle and cardiac tissue declines measurably with age. Cardiolipin composition shifts from functional tetralinoleoyl CL toward oxidized species in older tissues. SS-31 addresses that shift mechanistically. The unanswered question is whether the magnitude of cardiolipin oxidation in a healthy 45-year-old produces a response large enough to feel or measure in practice. Replacing a slightly worn gasket in an otherwise functional engine is a different proposition from rebuilding an engine whose gasket is the primary failure point.

The safety data from TAZPOWER is genuinely reassuring for anyone evaluating long-term use. A total of 168 weeks of continuous human exposure, published in Genetics in Medicine in 2024, produced no serious systemic adverse events. Injection site reactions occurred in roughly one-third of participants and responded to topical steroids or antihistamines without trial discontinuation. No hormonal suppression, no cortisol effects, no receptor desensitization pattern comparable to growth hormone secretagogues.

What dose does the evidence support for off-label use?

The TAZPOWER and MMPOWER-3 trials used 40 mg per day subcutaneously, which is also the approved dose for Barth syndrome. Phase 1 trials in healthy volunteers established safety across a range of 0.05 to 4 mg/kg. The off-label biohacker community converges on 5 to 10 mg per day as a starting protocol, scaling to 20 mg for specific cardiac or exercise recovery contexts. There is no published titration study supporting any specific off-label dose, so these numbers come from extrapolated safety data and community experience.

Context	Typical Protocol	Evidence Level	Key Source
Barth syndrome (approved use)	40 mg/day SC, continuous	Phase 3 RCT, FDA-approved	TAZPOWER, Genetics in Medicine 2024
Primary mitochondrial myopathy	40 mg/day SC (trial dose, failed endpoint)	Phase 3 RCT	MMPOWER-3, Neurology 2023
Heart failure, acute cardiac stress	IV single dose, 0.05-0.25 mg/kg	Phase 2 (positive acute signal)	PROGRESS-HF, Circulation Heart Failure
General longevity or biohacker	5-10 mg/day SC, 4-8 week cycles	Preclinical models, community data	No RCT in healthy adults completed

Cycling is common in the off-label community without strong biological justification. The TAZPOWER extension ran continuously for 168 weeks without evidence of tachyphylaxis or declining response. For longevity users, on/off cycling reflects cautionary habit rather than documented receptor biology. The peptide cycling protocol guide distinguishes compounds where cycling is mechanistically necessary from those where it is precautionary preference. SS-31 currently falls in the latter group based on available data.

SS-31 versus MOTS-c: which mitochondrial peptide actually fits your goals?

SS-31 and MOTS-c target mitochondria but through entirely different mechanisms, and most content conflates them because the word "mitochondrial" appears in both descriptions. Choosing the wrong one is a common and expensive mistake.

MOTS-c is encoded in the mitochondrial genome (12S rRNA gene) and circulates as a systemic metabolic hormone. It drives insulin sensitivity and metabolic flexibility through AMPK and FOXO pathways, rises during moderate exercise, and declines measurably with aging and type 2 diabetes. Its benefit is whole-body metabolic signaling. The MOTS-c guide covers what the K14Q mitochondrial variant means for how effectively this pathway runs in your specific biology.

SS-31 does not circulate as a hormone. It acts only at the cardiolipin-cytochrome c interface on the inner mitochondrial membrane. It does not improve insulin sensitivity, does not activate AMPK, and does not signal to the nucleus. It is a structural stabilizer, not a metabolic switch.

The selection framework is straightforward. If your primary concern is metabolic performance, insulin sensitivity, body composition, or energy as you age, MOTS-c matches the mechanism better. If your concern is cardiac or mitochondrial structural integrity under oxidative load, particularly in the context of known cardiolipin-related disease or documented mitochondrial energy production decline, SS-31 is the more targeted choice. The DNA-first peptide decision framework walks through how to map your goals and genotype to the right compound before committing to a protocol.

What your mitochondrial haplogroup predicts about SS-31 response

Your mitochondrial DNA haplogroup is inherited entirely from your mother and reflects tens of thousands of years of population-specific adaptation to different environments. Different haplogroups have measurably different baseline electron transport chain efficiencies, reactive oxygen species production rates, and cardiolipin compositional profiles. This is not theoretical. These differences are well-documented in aging cohort studies and population genetics research.

The haplogroup most relevant to SS-31 response is haplogroup J, carried by roughly 9 percent of people with Northern European ancestry. Haplogroup J includes a variant in the ND3 subunit of Complex I (m.10398A>G) that increases electron leak and reactive oxygen species production at baseline compared to the most common haplogroup H. That elevated electron leak is precisely the condition SS-31 addresses by stabilizing cardiolipin-anchored ETC supercomplexes. Several aging cohort studies find haplogroup J associated with faster mitochondrial function decline and higher oxidative stress in muscle tissue, consistent with elevated chronic cardiolipin turnover as the driver.

No SS-31 trial has been powered for haplogroup subgroup analysis, so this is a mechanistic prediction rather than clinical proof. The logic is the same as the Barth syndrome result: when the primary molecular problem is exactly what SS-31 targets, the response is dramatic. When it is not, MMPOWER-3 says expect nothing. Haplogroup J does not cause Barth syndrome. But among healthy adults with age-related mitochondrial decline, haplogroup J individuals face a higher cardiolipin oxidation burden than haplogroup H individuals, which makes the targeted mechanism more relevant rather than peripheral.

Nuclear genetics layer on top of this. The A16V variant (rs4880) in SOD2 reduces mitochondrial superoxide scavenging efficiency at Complex II. If you carry both haplogroup J and a low-activity SOD2 variant, the oxidative stress reaching your cardiolipin is substantially higher than average. TFAM gene variants affect how quickly mitochondria upregulate their own repair and biogenesis programs in response to damage accumulation. Low TFAM activity compounds the aging trajectory that SS-31 addresses structurally.

The most actionable genetic question is whether your primary mitochondrial bottleneck involves cardiolipin specifically. If your haplogroup and nuclear oxidative stress variants converge on elevated cardiolipin turnover, SS-31 has real pathology to address. If your mitochondrial weakness is primarily biogenesis, NAD+ depletion, or a different assembly pathway, SS-31 is targeting the wrong point. A peptide report that covers haplogroup, SOD2, and TFAM alongside the broader oxidative stress variant panel gives you the information needed to make that call. You can upload existing raw data from 23andMe or AncestryDNA at peptidesdna.com/upload, or read the 23andMe peptide guide to understand what consumer array data captures about your mitochondrial profile before you start.